Ryan Cohlhepp - 26 Dec 2025 Form 4 Insider Report for Bicara Therapeutics Inc. (BCAX)

Role
President and COO, Director
Signature
/s/ Lara Meisner, Attorney-in-Fact
Issuer symbol
BCAX
Transactions as of
26 Dec 2025
Net transactions value
+$110,922
Form type
4
Filing time
29 Dec 2025, 17:18:10 UTC
Previous filing
16 Dec 2025
Next filing
20 Jan 2026
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Cohlhepp Ryan President and COO, Director BICARA THERAPEUTICS INC., 116 HUNTINGTON AVENUE, SUITE 703, BOSTON /s/ Lara Meisner, Attorney-in-Fact 29 Dec 2025 0002034665

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction BCAX Common Stock Options Exercise $110,922 +25,000 +13% $4.44 214,141 26 Dec 2025 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction BCAX Stock Option (Right to Buy) Options Exercise $0 -25,000 -39% $0.000000 39,909 26 Dec 2025 Common Stock 25,000 $4.44 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This is an ISO exercise and hold to acquire and retain direct share ownership of the issuer.
F2 The shares underlying this option vest in sixteen equal quarterly installments following October 4, 2022, subject to the Reporting Person's continued service on each such vesting date.